Building a better understanding of the burden of disease in familial chylomicronemia syndrome
Open accessAbstract
Familial chylomicronemia syndrome (FCS), also referred to as type 1 hyperlipoproteinemia or lipoprotein lipase deficiency, is a rare genetic lipid disorder characterized by severe elevations in cir...
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Other symptoms of FCS are recurrent pancreatitis, severe abdominal pain ranging from mild to incapacitating (with or without pancreatitis), hepatosplenomegaly, lipemic plasma, eruptive xanthomas, lipemia retinalis, and decreased quality of life.
“Other symptoms of FCS are recurrent pancreatitis, severe abdominal pain ranging from mild to incapacitating (with or without pancreatitis), hepatosplenomegaly, lipemic plasma, eruptive xanthomas, lipemia retinalis, 1,14,15 and decreased quality of life.13”
From Familial chylomicronemia syndrome: Bringing to life dietary recommendations throughout the life span (2018) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 10 · Cited by 28
- Authors
- Ahmad, Z., Halter, R., & Stevenson, M.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Akcea Therapeutics, MA, USA
- Corresponding author
- Stevenson, Michael
- Venue
- Expert Review of Clinical Pharmacology
- Publisher
- Informa UK Limited
- Published
- 2016-11-08
- Volume
- 10
- Issue
- 1
- Pages
- 1-3
- ISSN
- 1751-2433 (ISSN-L)
- 1751-2441
- OpenAlex
- W2533594244
- Cited by
- 28
- References
- 10
- Citations by year
- 2026: 3 · 2024: 4 · 2023: 1 · 2022: 3 · 2021: 4 · 2020: 2 · 2019: 4 · 2018: 5 · 2017: 2
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Expert Review of Clinical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Akcea Therapeutics
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Surgery › Lymphatic Disorders and Treatments
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Keywords
- familial chylomicronemia syndrome, lipoprotein lipase deficiency, genetic lipid disorders, disease burden, hypertriglyceridemia, rare genetic disorders
- MeSH terms
- Humans, Hyperlipoproteinemia Type I, Cost of Illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
